Hjortrup Peter B, Haase Nicolai, Wetterslev Mik, Perner Anders
Crit Care. 2013 Apr 24;17(2):211. doi: 10.1186/cc11855.
Neutrophil gelatinase-associated lipocalin (NGAL) may be an early marker of acute kidney injury (AKI), but elevated NGAL occurs in a wide range of systemic diseases. Because intensive care patients have high levels of comorbidity, our objective was to conduct a systematic review of the literature to evaluate the value of plasma and urinary NGAL to predict AKI in these patients. We conducted a systematic electronic literature search of MEDLINE through PubMed, EMBASE, and Cochrane Library for all English language research publications evaluating the predictive value of plasma or urinary NGAL (or both) for AKI in adult intensive care patients. Two authors independently extracted data by using a standardized extraction sheet including study characteristics, type of NGAL measurements, and type of outcome measures. The primary summary measure was area under receiver operating characteristic curve (AuROC) for NGAL to predict study outcomes. Eleven studies with a total of 2,875 (range of 20 to 632) participants were included: seven studies assessed urinary NGAL and six assessed plasma NGAL. The included studies varied in design, including observation period from NGAL sampling to AKI follow-up (range of 12 hours to 7 days), definition of baseline creatinine value, and urinary NGAL quantification method (normalizing to urinary creatinine or absolute concentration). AuROC values for the prediction of AKI ranged from 0.54 to 0.98. Five studies reported AuROC for use of renal replacement therapy ranging from 0.73 to 0.89, and four studies reported AuROC for mortality ranging from 0.58 to 0.83. There were no differences in the predictive values of urinary and plasma NGAL. The heterogeneity in study design and results made it difficult to evaluate the value of NGAL to predict AKI in intensive care patients. NGAL seems to have reasonable value in predicting use of renal replacement therapy but not mortality.
中性粒细胞明胶酶相关脂质运载蛋白(NGAL)可能是急性肾损伤(AKI)的早期标志物,但在多种全身性疾病中NGAL水平都会升高。由于重症监护患者存在高度合并症,我们的目的是对文献进行系统综述,以评估血浆和尿液NGAL对预测这些患者发生AKI的价值。我们通过PubMed、EMBASE和Cochrane图书馆对MEDLINE进行了系统的电子文献检索,以查找所有评估血浆或尿液NGAL(或两者)对成年重症监护患者AKI预测价值的英文研究出版物。两位作者使用标准化提取表独立提取数据,提取内容包括研究特征、NGAL测量类型和结局测量类型。主要汇总指标是NGAL预测研究结局的受试者工作特征曲线下面积(AuROC)。纳入了11项研究,共有2875名(范围为20至632名)参与者:7项研究评估了尿液NGAL,6项评估了血浆NGAL。纳入的研究在设计上各不相同,包括从NGAL采样到AKI随访的观察期(范围为12小时至7天)、基线肌酐值的定义以及尿液NGAL定量方法(根据尿肌酐进行标准化或绝对浓度)。预测AKI的AuROC值范围为0.54至0.98。五项研究报告了使用肾脏替代治疗的AuROC,范围为0.73至0.89,四项研究报告了死亡率的AuROC,范围为0.58至0.83。尿液和血浆NGAL的预测价值没有差异。研究设计和结果的异质性使得难以评估NGAL对预测重症监护患者AKI的价值。NGAL在预测肾脏替代治疗的使用方面似乎具有合理价值,但对死亡率的预测价值不大。